This invention relates to a musculoskeletogenic MSG graft composite made from whole bone marrow aspirate BMA having native levels of musculoskeletal progenitor cells MSPCs, comprising:a) a suspension of fractionated BMA comprising:i) MSPCs present at a level greater than their native level in whole BMA, andii) red blood cells RBCs present at a level less than their native level in whole BMA, andb) a porous sterile matrix having an average pore size of at least 20 μm.
